Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.41 |
| ▸ | LMNA | P02545 | 3/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.40 |
| ▸ | POLB | P06746 | 2/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.38 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | CASP1 | P29466 | 1/20 | 0.37 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16478277 | 0.85 | TSHR (0.44) | TSHRLMNASMN1; SMN2POLBGAA | |
| SCHEMBL1805850 | 0.77 | POLB (0.61) | TSHRLMNASMN1; SMN2POLBGAA | |
| SCHEMBL16733792 | 0.75 | OPRM1 (0.50) | TSHRLMNASMN1; SMN2POLBGAA | |
| SCHEMBL16458858 | 0.75 | SMN1; SMN2 (0.47) | TSHRLMNASMN1; SMN2POLBGAA | |
| SCHEMBL17394413 | 0.74 | USP2 (0.44) | LMNASMN1; SMN2POLBGAAMAPT | |
| SCHEMBL5245605 | 0.68 | GAA (0.50) | TSHRLMNASMN1; SMN2POLBGAA | |
| SCHEMBL6128170 | 0.66 | KDM4E (0.55) | TSHRLMNASMN1; SMN2POLBKMT2A | |
| SCHEMBL6117914 | 0.65 | KDM4E (0.62) | TSHRLMNAPOLBGAAMAPT | |
| SCHEMBL15556032 | 0.64 | HTR3E (0.43) | TSHRMAPTKDM4ECASP1HSD17B10 | |
| SCHEMBL15555806 | 0.64 | CYP2C9 (0.39) | TSHRPOLBMAPTCYP2C9KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2870143-B1 | TRIAZOLE COMPOUNDS AS ANTIVIRALS | HOFFMANN LA ROCHE (CH) | 2017-05-17 | — | — | EP | disclosed |
| US-20150307461-A1 | ANTIVIRAL COMPOUNDS | HOFFMANN-LA ROCHE INC. (US) | 2015-10-29 | — | — | US | disclosed |
| EP-2870143-A1 | TRIAZOLE COMPOUNDS AS ANTIVIRALS | F. Hoffmann-La Roche AG (CH) | 2015-05-13 | — | — | EP | disclosed |
| US-20140010783-A1 | ANTIVIRAL COMPOUNDS | HOFFMANN-LA ROCHE INC. | 2014-01-09 | — | — | US | disclosed |
| WO-2014006066-A1 | TRIAZOLE COMPOUNDS AS ANTIVIRALS | F. HOFFMANN-LA ROCHE AG (CH) | 2014-01-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150307461-A1 | ANTIVIRAL COMPOUNDS | HAVCR2, EIF2AK2, MAVS | TSHR 4602/4885LMNA 3929/4885SMN1; SMN2 2853/4885 |
| US-20140010783-A1 | ANTIVIRAL COMPOUNDS | HAVCR2, EIF2AK2, MAVS | TSHR 4602/4885LMNA 3929/4885SMN1; SMN2 2853/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.